Focus: Dragonfly Therapeutics is a publicly traded immuno-oncology biotech focused on developing novel therapies for solid tumors through advanced immunological approaches. The company operates from Waltham, MA with a pipeline of early-stage oncology programs.
Profile data last refreshed 23m ago · AI intelligence enriched 1w ago
Dragonfly offers early-stage oncology exposure with public company benefits, but minimal hiring and an immature pipeline limit near-term career growth and stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dragonfly Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dragonfly Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Bill Haney’s Dragonfly nabs former Cerevel CFO; Cellectis’ new CMO - Endpoints News
Bill Haney’s Dragonfly nabs former Cerevel CFO; Cellectis’ new CMO Endpoints News
EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight - PR Newswire
EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight PR Newswire
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo